4. How were the subjects screened for other causes of fatty liver (e.g. autoimmune hepatitis, hemochromatosis etc.) than NAFLD and AFLD? 5. The amount of alcohol intake is crucial for this analysis. The authors need to specifically state how they evaluated alcohol intake. 6. How was smoking (number of cigarettes per day, duration in years, active smoking during the first evaluation) evaluated? 7. How many subjects were lost to follow-up? 8. It is absolutely unexpected that, in contrast to most other studies, fatty liver was not at all associated with a higher BMI. More strikingly, the higher waist circumference in fatty liver was present, as expected. As fatty liver also correlates independently of other anthropometrics, with height (Lancet Diabetes Endocrinol. 2016 May;4(5):457-67.) may differences in height explain these relationships? 9. When the authors discuss the association between NAFLD and mortality in the general population, they should report on the most recently published study conducted in 318,224 subjects in this field of research (Clin Gastroenterol Hepatol. 2018 Jul; 16(7) :1131-1137.e5.) and address how these data relate to other studies in this field of research (see for details Clin Gastroenterol Hepatol. 2018 Jul;16(7):1043-1045.).
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GENERAL COMMENTS
Caruco, MG et al explored the association between fatty liver as detected by echography and its severity with all-cause mortality among patients with NAFLD or ALD followed by a median of 12 years. Authors confirmed that fatty liver is not associated with all-cause mortality after adjusting by several confounders and these results support previous observations, that US enables an accurate diagnosis of hepatic steatosis but the presence of steatosis does not predict risk of overall and cause-specific mortality. It is well known that presence of fibrosis rather than steatosis in an important long-term predictor of not only all-cause mortality but also hepatic decompensation, HCC, non-hepatic malignancies and cardiovascular events. 
In the study "Fatty Liver and Mortality: A Population Study in a Mediterranean Area", the authors attempt to address an important question -does the presence of steatosis (NAFLD) increase mortality. The design was clearly stated and the authors present their data clearly, however I have some criticisms of the paper.
1. This is a very narrow population and is relatively small to address this question and I am not sure about the generalizability of these results.
2. There is limited follow up at only 12 years. For a disease of relatively indolent progression, 12 years to assess for a mortality end point is a relatively short period. 3. The authors excluded the 17 patients with cirrhosis from their analysis and while I can understand that they wanted to focus on steatosis, they have essentially excluded the patients with the most progressive disease and one could argue this is the group at highest mortality risk. If you select out these patients and then follow a group that was ~ 65 years old on average for only 12 years, you are essentially selecting out the group where the liver disease would likely have the least impact and therefore it is probably of no surprise there was no impact on mortality. 4. While I can appreciate the effort to identify some 'severity' of steatosis, it is not correct to assume that more steatosis implies more severe liver disease. I would probably limit the analysis simply to if steatosis was present or not and not necessarily try to grade the disease severity with an imperfect non-invasive assessment such as ultrasound. 5. As the authors note, the co-morbid conditions are self reported and this is a limitation 6. It is not clear why the authors noted the presence of gastric ulcer or gallstones. This should be explained further. 7. The discrepancy between the waist circumference and the BMI is notable in the groups, particularly as the authors noted in their methods there was high collinearity between waist circumference and BMI. This warrants further explanation.
Thank you

VERSION 1 -AUTHOR RESPONSE
Reviewer(s)' Comments to Author:
Reviewer: 1 1. Introduction: The authors need to much more in detail address the findings from the major published studies that investigated the relationships of NAFLD and the severity of NAFLD with total and cause-specific mortality (e.g. , and liver cirrhosis.
1 Metabolic conditions associated with NAFLD included obesity, present in more than half of the people, type 2 diabetes, hyperlipidemia, hypertension, and metabolic syndrome.
5 Liver-specific mortality and overall mortality in NAFLD patients is estimated in 0.77 persons per 1,000.
5 However, the role of potential confounders seems to be important for explaining the association between the presence of liver steatosis and these medical conditions. For example, the association between liver steatosis and the onset of cardiovascular diseases disappeared after the adjustment for potential confounders (e.g. the presence of adiposity and diabetes) in some studies.
8 Finally, because NAFLD is a heterogeneous disease, the advanced stages of which seem to be strongly affected by medical conditions (particularly insulin resistance and type 2 diabetes), further modifying the association between liver steatosis and mortality. 9 " 2. The authors need to provide more information about the selection of their study population; e.g. how were subjects contacted (letters, newspapers …), what was the age range, were specific diseases excluded a priori, what was the main aim for contacting the subjects?
Reply: We have better explained the selection criteria as follows:
"No a priori selection criteria were used for the MICOL study in terms of age and comorbidities. The participants were enrolled through contact with their general practitioners." 3. What was the patient's medication? Adjustment for pharmacological treatment needs to be done.
Reply: In the MICOL study, we did not extensively asked information regarding medication, having available only information regarding some diseases, such as dyslipidemia, diabetes, gastric ulcer and some others. Thus, in our opinion, it is not feasible to adjust for this covariate. We have added this as important limitation of our study, as follows: "Finally, the information regarding co-morbidities are self-reported and this could introduce another bias such as we don't have any complete information regarding medications that, on the contrary, may significantly alter the association between liver steatosis and mortality." 4. How were the subjects screened for other causes of fatty liver (e.g. autoimmune hepatitis, hemochromatosis etc.) than NAFLD and AFLD?
Reply: Good point. These specific diseases were self-reported, based on medical history. We have now added these details in the text.
5. The amount of alcohol intake is crucial for this analysis. The authors need to specifically state how they evaluated alcohol intake.
Reply: We have added the following sentence in the Methods section:
"Alcohol intake was determined using the FFQ, as stated before, using the intake of wine, beer, super-alcoholic drinks." 6. How was smoking (number of cigarettes per day, duration in years, active smoking during the first evaluation) evaluated?
Reply: Thank you for your question. We have now added this sentence in the Methods section as follows:
"Finally, self-reported information regarding smoking status (active or previous smoking during the first evaluation vs. never)." 7. How many subjects were lost to follow-up?
Reply: 79 subjects did not have any information regarding mortality status and so we considered them as lost at follow-up. We have now added this important detail in the text.
8. It is absolutely unexpected that, in contrast to most other studies, fatty liver was not at all associated with a higher BMI. More strikingly, the higher waist circumference in fatty liver was present, as expected. As fatty liver also correlates independently of other anthropometrics, with height (Lancet Diabetes Endocrinol. 2016 May;4(5):457-67.) may differences in height explain these relationships?
Reply: We sincerely thank the Reviewer for observing this unexpected finding. Here the association between liver steatosis and anthropometric parameters by alcohol intake that show an association between liver steatosis and waist and not BMI. We don't have any simple justification of these findings, contrary to those reported by other studies. However, we would like to note that abdominal obesity is more strictly correlated with NAFLD than obesity per se, as shown by several papers.
NAFLD
We acknowledge this as potential limitation of our study, as follows:
"Thirdly, contrary to our expectations, BMI was not different between people having or not NAFLD. We can hypothesize that, in our study, only abdominal obesity is strictly associated with the presence of NAFLD, whilst obesity per se no, further confirming a peculiar association between waist circumference and this condition.
"
9. When the authors discuss the association between NAFLD and mortality in the general population, they should report on the most recently published study conducted in 318,224 subjects in this field of research (Clin Gastroenterol Hepatol. 2018 Jul;16(7):1131-1137.e5.) and address how these data relate to other studies in this field of research (see for details Clin Gastroenterol Hepatol. 2018 Jul;16(7):1043-1045.).
Reply: We really appreciate that the Reviewer suggested us these two important works. We have commented as follows, their findings:
"Only recently a large study made in 318,224 people in Korea reported a significant association between NAFLD and mortality (all-cause and specific), but these findings were significant only in women and, surprisingly, in obese men, NAFLD was associated with a reduced risk of death from cancer. 27 As correctly observed by dr. Stefan in an Editorial, it is likely that women involved in this study and having NAFLD clearly had a higher cardiometabolic risk profile, which might have increased the power to detect relationships of NAFLD with mortality.
28"
Reviewer: 2 Please leave your comments for the authors below Caruco, MG et al explored the association between fatty liver as detected by echography and its severity with all-cause mortality among patients with NAFLD or ALD followed by a median of 12 years.
Authors confirmed that fatty liver is not associated with all-cause mortality after adjusting by several confounders and these results support previous observations, that US enables an accurate diagnosis of hepatic steatosis but the presence of steatosis does not predict risk of overall and cause-specific mortality. It is well known that presence of fibrosis rather than steatosis in an important long-term predictor of not only all-cause mortality but also hepatic decompensation, HCC, non-hepatic malignancies and cardiovascular events.
